首页 > 市场调查报告书 > 製药

非专利药糖尿病生物製剂生技仿製药

胰岛素市场规模、份额和成长分析（按产品类型、给药装置、类型、应用、分销管道和地区划分）：产业预测（2026-2033 年）

市场调查报告书

商品编码

1898001

胰岛素市场规模、份额和成长分析（按产品类型、给药装置、类型、应用、分销管道和地区划分）：产业预测（2026-2033 年）

Insulin Market Size, Share, and Growth Analysis, By Product Type (Rapid-Acting Insulin, Long-Acting Insulin,), By Delivery Device (Pens, Infusion Pumps), By Type, By Application, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月22日 | 出版商:

SkyQuest | 英文 192 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，胰岛素市场规模将达到 213.1 亿美元，到 2025 年将达到 216.3 亿美元，到 2033 年将达到 244.1 亿美元，在预测期（2026-2033 年）内，复合年增长率为 1.52%。

受糖尿病盛行率上升和药物研发取得重大进展的推动，胰岛素市场经历了显着增长。然而，来自GLP-1受体促效剂和其他第二型糖尿病治疗药物的竞争可能会阻碍这种扩张。该行业仍处于寡占状态，诺和诺德、赛诺菲和礼来等主要企业占据了相当大的市场份额。糖尿病是全球成长最快的慢性疾病之一，目前影响着超过5亿成年人，这推动了对有效治疗方法的需求。生产流程的创新正在推动市场动态，例如PhiAspi吸收率的提高以及目前唯一的吸入式胰岛素Afrezza（无需注射）。此外，Oramed的口服胰岛素胶囊等前景广阔的研发成果可望彻底改变糖尿病的治疗方式。

胰岛素市场驱动因素

全球糖尿病发生率的不断上升是胰岛素市场的主要驱动因素。久坐不动的生活方式、不良的饮食习惯以及日益严重的肥胖问题，都显着加剧了第1型和第2型糖尿病病例的增加。因此，人们对传统和创新胰岛素疗法的需求日益增长，以帮助控制血糖值。这一趋势在亚洲和非洲的都市区尤其明显，当地生活方式和饮食习惯的改变进一步加速了对胰岛素产品的需求。不断成长的患者群体推动了市场的扩张，也凸显了有效糖尿病管理解决方案的紧迫性。

胰岛素市场限制因素

胰岛素市场面临的一大挑战是胰岛素治疗费用高昂，这构成了一大障碍，尤其是在医疗资源匮乏的地区。创新长效胰岛素类似物的价格可能令人望而却步，限制了低收入患者的用药。在医疗保险体系薄弱或缺乏的开发中国家，这种经济负担尤其突出，严重阻碍了患者获得必要的糖尿病治疗。这种情况凸显了迫切需要更经济实惠的解决方案，以确保所有患者，无论其经济状况或地理位置如何，都能获得所需的胰岛素并有效控製糖尿病。

胰岛素市场趋势

随着传统胰岛素专利到期，胰岛素市场正经历着向生物相似药的显着转变。这项转变的驱动力在于人们日益认识到生物相似药的成本效益，它们以更低的价格提供与传统胰岛素相当的治疗效果。监管机构正发挥关键作用，他们加强了这些替代药物的核准流程，有助于营造竞争环境，最终可能降低整体医疗成本。因此，患者，尤其是在胰岛素价格历来较高的地区，将更容易获得糖尿病管理方案，这将进一步推动市场对生物相似胰岛素的需求，并改变现有的治疗模式。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Eli Lilly and Company
Sanofi
Novo Nordisk A/S
Biocon
Boehringer Ingelheim International GmbH
Tonghua Dongbao Pharmaceutical Co. Ltd.
Wockhardt
Julphar
Novo Nordisk
Merck & Co., Inc.
Pfizer Inc.
AstraZeneca
Johnson & Johnson
Biocon Ltd.
Ypsomed AG
Gan & Lee Pharmaceuticals
Bioton SA
Adocia
Torrent Pharmaceuticals Ltd.
Ipsen
Dongbao Enterprise Group Co., Ltd.

简介目录

Product Code: SQMIG35A2943

Insulin Market size was valued at USD 21.31 Billion in 2024 and is poised to grow from USD 21.63 Billion in 2025 to USD 24.41 Billion by 2033, growing at a CAGR of 1.52% during the forecast period (2026-2033).

The insulin market is experiencing notable growth driven by the rising prevalence of diabetes and significant advancements in drug development. However, competition from GLP-1 receptor agonists and other medications for type 2 diabetes may hinder this expansion. This sector remains largely oligopolistic, with major players like Novo Nordisk, Sanofi, and Eli Lilly commanding substantial market shares. As one of the most rapidly increasing chronic health concerns globally, diabetes now affects over half a billion adults, pushing demand for effective treatments. Innovations in manufacturing processes are propelling market dynamics, exemplified by products like Fiasp, which enhances absorption, and Afrezza, the sole inhalable insulin option that negates the need for needles. Additionally, promising developments such as Oramed's oral insulin capsules are on the horizon, potentially reshaping the treatment landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Insulin Market Segments Analysis

Global Insulin Market is segmented by Product Type, Delivery Device, Type, Application, Distribution Channel, and Region. Based on Product Type, the market is segmented into Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar, Others. Based on Delivery Devices, the market is segmented into Pens, Infusion Pumps, Syringes, and Others. Based on Type, the market is segmented into Human Insulin, Insulin Analog. Based on Application, the market is segmented into Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Insulin Market

The insulin market is primarily influenced by the growing incidence of diabetes worldwide. Factors such as sedentary lifestyles, poor dietary habits, and escalating obesity rates are significant contributors to the rise in both type 1 and type 2 diabetes cases. As a consequence, there is a heightened demand for insulin therapies, both traditional and innovative, to help manage blood glucose levels. This trend is particularly noticeable in urban regions of Asia and Africa, where shifts in lifestyle and dietary patterns further propel the need for insulin products. This increasing patient population underscores the market's expansion, highlighting the urgent need for effective diabetes management solutions.

Restraints in the Insulin Market

A significant challenge in the insulin market is the elevated cost of insulin therapy, which poses a barrier, particularly in regions with limited healthcare access. The price of innovative, long-acting insulin analogs can be prohibitively expensive, restricting access for low-income patients. These financial burdens are especially pronounced in developing nations, where healthcare reimbursement systems may be insufficient or entirely absent, leading to significant obstacles in obtaining essential diabetes treatment. This situation highlights the urgent need for more affordable solutions to ensure that all patients, regardless of their financial status or geographic location, can access the insulin they require for effective diabetes management.

Market Trends of the Insulin Market

The insulin market is witnessing a notable trend towards biosimilar insulin products as patents for traditional insulins expire. This transition is driven by growing recognition of the cost-effectiveness of biosimilars, which offer similar therapeutic benefits at reduced prices. Regulatory agencies are playing a pivotal role by enhancing the approval processes for these alternatives, fostering a more competitive landscape that can potentially lower overall healthcare expenses. As a result, patients, especially in regions with previously high insulin costs, may experience improved access to diabetes management options, further fueling the market demand for biosimilar insulins and transforming treatment paradigms.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Patent Analysis
Regulatory Landscape
PESTEL Analysis
Pipeline Analysis
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition
Customer & Buying Criteria Analysis

Insulin Market by Product Type

Market Overview
Rapid-Acting Insulin
- Insulin Lispro
- Insulin Lispro
- Insulin Glulisine
- Technosphere insulin
Long-Acting Insulin
- Insulin Detemir
- Insulin Glargine
- Insulin Glargine-yfgn
- Insulin Degludec
Combination Insulin
- NPH/Regular
- Protamine/Lispro
- Protamine/Aspart
Biosimilar
Others

Insulin Market by Delivery Device

Market Overview
Pens
Infusion Pumps
Syringes
Others

Insulin Market by Type

Market Overview
Human Insulin
Insulin Analog

Insulin Market by Application

Market Overview
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Insulin Market by Distribution Channel

Market Overview
Hospitals
Retail Pharmacies
Others

Insulin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tonghua Dongbao Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wockhardt
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Julphar
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ypsomed AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gan & Lee Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioton S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adocia
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Torrent Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dongbao Enterprise Group Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments